+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) - Drugs In Development, 2021

  • ID: 5359599
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 80 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Amgen Inc
  • Biogen Inc
  • Coda Biotherapeutics Inc
  • Grace Therapeutics LLC
  • InMed Pharmaceuticals Inc
  • Noema Pharma AG
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Drugs In Development, 2021, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape.

Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain or attacks triggered by things such as touching the face, chewing, speaking and brushing teeth, pain in areas supplied by the trigeminal nerve, including the cheek, jaw, teeth, gums, lips, or less often the eye and forehead.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Trigeminal Neuralgia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia (Tic Douloureux) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 2 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Trigeminal Neuralgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Trigeminal Neuralgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Trigeminal Neuralgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • Biogen Inc
  • Coda Biotherapeutics Inc
  • Grace Therapeutics LLC
  • InMed Pharmaceuticals Inc
  • Noema Pharma AG
  • MORE
Introduction
  • Report Coverage
Trigeminal Neuralgia (Tic Douloureux) - Overview

Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Trigeminal Neuralgia (Tic Douloureux) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Trigeminal Neuralgia (Tic Douloureux) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Coda Biotherapeutics Inc
  • Grace Therapeutics LLC
  • InMed Pharmaceuticals Inc
  • Noema Pharma AG
  • Noveome Biotherapeutics Inc
  • OliPass Corporation
  • Praxis Precision Medicines Inc
  • USA Elixiria Biotech Inc
Trigeminal Neuralgia (Tic Douloureux) - Drug Profiles

DKI-561 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ELB-00824 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
erenumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Gene Therapy for Trigeminal Neuralgia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
GTX-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
INM-405 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NOE-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
OLP-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
PRAX-562 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
rimegepant sulfate ODT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ST-266 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
vixotrigine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects

Trigeminal Neuralgia (Tic Douloureux) - Product Development Milestones

Featured News & Press Releases
  • Jul 03, 2019: Biohaven starts enrolment in rimegepant’s trigeminal neuralgia trial
  • Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy
  • Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study
  • Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
  • Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study
  • Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802
  • Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Amgen Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biogen Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Coda Biotherapeutics Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Grace Therapeutics LLC, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by InMed Pharmaceuticals Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noema Pharma AG, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Noveome Biotherapeutics Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by OliPass Corporation, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by Praxis Precision Medicines Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Pipeline by USA Elixiria Biotech Inc, 2021
  • Trigeminal Neuralgia (Tic Douloureux) - Dormant Projects, 2021
List of Figures
  • Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Amgen Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Coda Biotherapeutics Inc
  • Grace Therapeutics LLC
  • InMed Pharmaceuticals Inc
  • Noema Pharma AG
  • Noveome Biotherapeutics Inc
  • OliPass Corporation
  • Praxis Precision Medicines Inc
  • USA Elixiria Biotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll